Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Science Clips
COVID-10 GPH

Last data update: Jan 13, 2025. (Total: 48570 publications since 2009)
(Author names in bold with hyperlink are CDC authors)
Filtered By:
Order By:
Records 1-1 (of 1 Records)
Query Trace: Coleman-McCray JAD[original query]
Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains.
Spengler JR , Kainulainen MH , Welch SR , Coleman-McCray JAD , Harmon JR , Condrey JA , Scholte FEM , Nichol ST , Montgomery JM , Albariño CG , Spiropoulou CF .
J Infect Dis 2022 226 (9) 1545-1550 type

Lassa virus (LASV) causes mild to severe hemorrhagic fever disease in humans. Strain 13/N guinea pigs are highly susceptible to infection with LASV strain Josiah (clade IV), providing a critical model system for therapeutics and vaccine development. To develop additional models of disease, we detail the clinical course in guinea pigs infected with 5 geographically and genetically diverse LASV strains. Two of the developed models (LASV clades II and III) were then used to evaluate efficacy of a virus replicon particle (VRP) vaccine against heterologous LASV challenge, demonstrating complete protection against clinical disease after a single vaccination dose.
TOP